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Eosinophilic bronchitis is a common cause of chronic cough, which like asthma is characterized by sputum eosinophilia, but
unlike asthma there is no variable airﬂow obstruction or airway hyperresponsiveness. Several studies suggest that prostaglandins
may play an important role in orchestrating interactions between diﬀerent cells in several inﬂammatory diseases such as asthma.
PGE2 is important because of the multiplicity of its eﬀects on immune response in respiratory diseases; however, respiratory
system appears to be unique in that PGE2 has beneﬁcial eﬀects. We described that the diﬀerence in airway function observed
in patients with eosinophilic bronchitis and asthma could be due to diﬀerences in PGE2 production. PGE2 present in induced
sputum supernatant from NAEB patients decreases BSMC proliferation, probably due to simultaneous stimulation of EP2 and
EP4 receptors with inhibitory activity. This protective eﬀect of PGE2 may not only be the result of a direct action exerted on airway
smooth-muscle proliferation but may also be attributable to the other anti-inﬂammatory actions.
1.Introduction
Asthma has consistently been reported as a major cause
of chronic cough [1]. The development of noninvasive
assessment of airway inﬂammation led to the identiﬁcation
of a condition that manifests chronic cough in individuals
without the abnormalities of airway function that charac-
terize asthma, but with sputum eosinophilia. This condition
was named nonasthmatic eosinophilic bronchitis (NAEB)
[2]. The reason for the absence of airway hyperresponsive-
ness in the NAEB remains unclear. Inﬂammation of the
airways, with recruitment and activation of T lymphocytes,
eosinophils, and mast cells and release of inﬂammatory
mediators, plays an important role in the pathophysiology
of asthma and NAEB. Among lipid mediators, PGE2 is a
mediator thought to have an important role.
Thispapershallsummarizeourcurrentknowledgeofthe
roleofPGE2 inlungandinrespiratorydiseasesuchasasthma
and nonasthmatic eosinophilic bronchitis.
2.PGE2 Biosynthesis
Several studies suggest that prostaglandins may play
an important role in orchestrating interactions between
diﬀerent cells in several inﬂammatory diseases such as
asthma and rheumatoid arthritis.
Although the term prostaglandin was coined in the 1930s
by Von Euler [3], and Bergstrom and Samuelsson deﬁned
the structure of two ﬁrst prostaglandins in 1960 [4], the
full structure of prostaglandins was not identiﬁed until
1965 by Orloﬀ. Prostaglandins are arachidonic acid (AA)
metabolites which result from enzymes with cyclooxygenase
(COX) activity [5]. These metabolites are small lipidic
molecules implicated in the regulation of many diﬀerent
processes in the organism. Their production begins with
the liberation of AA from membrane phospholipids by
phospholipase A2 in response to inﬂammatory stimuli [6].
AA is then transformed into prostaglandin H2 (PGH2)b y
COXs, which is the ﬁrst step in eicosanoid biosynthesis.
PGH2 is an unstable molecule that is transformed into
several biologically active prostaglandins through speciﬁc
enzymes with diﬀerent tissue and cellular expression pattern
[7].
Two isoforms of COX have been identiﬁed, and they
are classiﬁed as COX-1 and COX-2. The main diﬀerences
between them are their expression regulation and tissue
distribution. In terms of expression, COX-1 is constitutively2 Mediators of Inﬂammation
expressed in cells in which prostaglandins exert physiolog-
ical functions, while COX-2 expression is enhanced after
inﬂammatory stimuli [8], such as LPS, several proinﬂamma-
tory cytokines (tumor necrosis factor-alpha, interleukin-1-
beta), growth factors, or tumoral promoter as PMA [4, 9].
Both isoforms catalyze similar reactions although they are
codiﬁed by diﬀerent genes [10]. COX-1 is associated with
immediate biosynthesis of prostaglandins (several minutes
after stimulation) which develop homeostatic functions;
COX-2 is linked to delayed biosynthesis of prostaglandins
(several hours after stimulus) which exert pathological
eﬀects. Other diﬀerence is the cellular localization; thus,
COX-1 is expressed in endoplasmic reticulo, whereas COX-2
is situated in perinuclear membrane [7, 11].
PGE2 is the most abundantly produced prostanoid in the
body and has been shown to play an important role in reg-
ulating inﬂammatory processes. PGE2 production is largely
dependent upon three enzymatic reactions: generation of
arachidonic acid from membrane glycerophospholipids via
phospholipase A2, conversion of AA to an unstable inter-
mediate prostanoid (PGH2) by COXs, and metabolism of
prostaglandin H2 to prostaglandin E2 via prostaglandin E
synthase [12].
There are three enzymes that catalyze PGE2 genera-
tion starting from PGH2, namely, membrane-bound PGES
(mPGES)-1[13],mPGES-2[14],andcytosolicPGE(cPGES)
[15] which constitute two biosynthetic pathways to PGE2
secretion; on one hand, COX-1/cPGES, the pathway impli-
cated in homeostasis and does not play an important role in
PGE2 production [16], and on the other, COX-2/mPGES-1,
thepathwayassociatedwithdelayedresponse,inﬂammation,
and pathology [17], and that is essential for basal production
in some organs as brain, spleen, and stomach (at least in
mice) [18].
Major cellular sources of PGE2 include epithelial




G-protein-coupled membrane receptors (GPCRs) termed E-
prostanoid (EP) receptors. There are four GPCR subtypes:
EP1, EP2, EP3, and EP4 [20, 21]. Expression regulation
of the various subtypes of EP receptor by several agents,
such as inﬂammatory stimuli, or even PGE2 itself, enables
PGE2 to aﬀect tissues in a very speciﬁc and diverse manner
[22, 23] .T h e s es u b t y p e so fE Pr e c e p t o rd i ﬀer in the
intracellular signaling [24]. The expression or a combination
of receptors, each which may be diﬀerentially expressed in
a number of tissues (i.e., airway smooth muscle, neurons,
or immune eﬀector cells), results in a speciﬁc physiological
response. These receptors could be classiﬁed according to
their intracellular signaling and second messenger. EP1
receptor activation leads to an increase in intracellular
calcium, usually coupled to Gq protein, and its stimulation
is linked to phospholipase C [25]. EP2 and EP4 receptors
couple to Gs, and activation of these receptors results in
stimulation of adenylyl cyclase and increases intracellular
cAMP [26]. The major signaling pathway described for the
EP3 receptor is mediated by Gαi and leads to a reduction
in intracellular cAMP levels. However, several EP3 receptor
isoforms generated by alternative splicing from the single
EP3 receptor gene have been identiﬁed, and the intracellular
signal may diﬀer [27]. Some of these isoforms of the EP3
receptor coupled to multiple G proteins produced either
inhibition of adenylate cyclase and calcium mobilization
or stimulation of adenylate cyclase activity [26]. Thus,
accumulation of cAMP promoted by EP2 and EP4 receptors
is associated with the inhibition of eﬀector cell functions;
however, EP1 and some isoforms of the EP3 receptor that
increase intracellular calcium could be linked to promotion
of cellular activation [20].
In pathological conditions, the role of these receptors is
determined by pattern expression, ligand aﬃnity, and their
diﬀerential coupling to transduction signaling pathways in
which the cellular context of the receptor is very relevant.
4.PGE2 Effects on Respiratory System
PGE2 is almost ubiquitous in humans and evokes potent
diverse actions. It regulates several functions in the major
human systems, including the gastrointestinal, reproductive,
neuroendocrine, and immune systems [28].
It is in the area of inﬂammation that the actions of PGE2
are most diverse because of the many specialized cell types
as well as the complex and sometimes seemingly opposing
actions that make that PGE2 one of the most heterogeneous
eicosanoids. This complexity reﬂects diﬀerences between
endogenous formation and action versus pharmacological
and exogenous addition of PGE2 in vivo and in vitro [29].
PGE2 acts like a pleiotropic prostaglandin with stim-
ulating or inhibiting properties and could be classiﬁed as
a regulatory element of immunity [30]. An example of
this stimulating/inhibiting polarity is the opposite actions
that PGE2 exerts in the cardiovascular and immune system,
where PGE2 is able to enhance the inﬂammation caused by
leukotrienes as well as inhibit the release of mediators and
regulate monocyte macrophages and dendritic cells [31].
Although PGE2 acts in multiple systems, we will focus
our attention on the role that this prostaglandin plays in the
inﬂammatory process linked to respiratory system.
PGE2 is the major metabolite in the lower respiratory
tract. In this system, epithelium and airway smooth muscle
aretheprincipalsourceofPGE2 [32],thoughﬁbroblast,alve-
olar macrophages, and pulmonary endothelial cells also pro-
duce it [33, 34]. PGE2 is important because of the multiplic-
ity of its eﬀects on immune response in respiratory diseases.
PGE2 is commonly presumed to be a proinﬂammatory
mediator and has been implicated in several inﬂammatory
disease conditions, including rheumatoid arthritis [35];
however, PGE2 has protective eﬀects in diﬀerent organs, and
respiratory system appears to be one of them in that PGE2
has beneﬁcial eﬀects [26, 36–38].
During the 1970s, PGE2 was shown to protect against
bronchoconstriction produced by ultrasonically nebulized
distilled water [39] and exercise-induced asthma [40]. In
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PGE2 protected against bronchial hyperreactivity to sodium
metabisulphite in which bronchoconstriction is thought to
be neurally mediated. In this study, furosemide protected
against bronchoconstrictor challenges in asthma, and this
eﬀect may be mediated through PGE2. Multiple subsequent
studies have observed the bronchodilator eﬀect of PGE2
in normal subjects [42] and patients with asthma and
chronic bronchitis [43], showing that PGE2 attenuates
bronchoconstriction, possibly inhibiting the release of the
bronchoconstrictor mediators which are responsible for
exercise bronchoconstriction. This prostanoid inhibits early
and late allergen-induced bronchoconstriction, increasing
the relaxation of airway smooth muscle and inhibiting
the release of mast-cell mediators and the recruitment of
inﬂammatory cells [34]. Moreover, PGE2 also decreases or
inhibits the accompanying bronchial hyperresponsiveness to
methacholine [36].
All these positive eﬀects of PGE2 are mainly mediated
through EP2 and EP4 receptors [44]. PGE2 can mediate
bronchodilation via the EP2 receptor [45] and also anti-
inﬂammatory eﬀects via the EP2 and/or the EP4 receptor
[46]. Also, EP2 plays an important role in aspirin-intolerant
asthma because a reduction in released PGE2 and lower
expression of its EP2 receptor provoked an increase in
inﬂammatory process in the airways of these patients [47].
However, PGE2 also induces irritation of the upper airway,
resulting in a reﬂex cough and enhancing the response to
capsaicin.Thecoughinginducedbythisprostanoid is caused
mainly, if not solely, by activation of the EP3 receptor, and in
bronchoconstrictor eﬀects are implicated by both EP1 and
EP3 receptors [48].
5.PGE2 andInﬂammatory Cells
Immune cells produce a variety of prostaglandins that have
both proinﬂammatory and anti-inﬂammatory eﬀects [49].
Eosinophils are one of predominant inﬂammatory cells in
the lungs of asthmatic patients, and changes in the number
and degree of lung eosinophils probably inﬂuence disease
severity. Peacock and colleagues demonstrated that PGE2
suppresses eosinophil apoptosis, and this is likely mediated
by interaction with the EP2 receptor subtype in eosinophils
[50], by contrast, misoprostol (a PGE2 analogue) inhibits
eosinophil survival in vitro [51]. Nevertheless, in recent
years, all studies have shown a negative regulator role
of PGE2 on eosinophils. This prostanoid directly controls
eosinophils’ migration on the cellular levels and is highly
potentandeﬃcacious.Thiseﬀectisbroughtaboutmainlyby
EP2 receptor involving PI3K- and PKC-dependent pathways
[52]. Furthermore, PGE2 not only attenuates eosinophil
traﬃcking but also abolishes the production of reactive oxy-
gen species, Ca2+ responses, and upregulation of adhesion
molecules through the EP4 receptor [53]. EP4 does not
seem to depend on activation of the adenylyl cyclase/PKA
pathway. Its stimulation causes phosphorylation of extra-
cellular signal-regulated kinases (ERKs) through a PI3K-
dependent mechanism [53]. So, an alternative EP2/EP4
signaling pathway in which both PI3K and PKC activation
are implicated has been postulated.
PGE2 also acts on T cells and alveolar macrophages. It is
able to decrease proliferation of lymphocytes, subsequently
decreasing the production of Th2 cytokines [54]. In another
study, PGE2 produced an increase of IL-10 expression,
an important regulatory cytokine [55]. In contrast, PGE2
positively controls the regulatory T cells (Treg) which are
pivotal in suppressing immune responses and maintaining
tolerance. PGE2 upregulates FOXP3 mRNA and protein
expression and enhances FOXP3 promoter activity [56].
PGE2 also enhances Ig class switch to IgE in B cells [57].
PGE2 is a route through which airway epithelial cells
(AECs) modulate speciﬁc cellular subtypes such as den-
dritic cells. Along these lines, Schmidt and colleagues [58]
demonstrated that epithelial cells, through the constitutive
secretion of PGE2, drive DCs to adopt an anti-inﬂammatory
phenotype in an EP4 receptor-dependent manner coupled to
cAMP production. As a result, PGE2-EP4 receptor signaling
generates DCs with reduced proinﬂammatory properties
(decreased production of TNF-α and enhancing IL-10
secretion), thereby limiting DC activation [58].
Also, in alveolar macrophages, it produces an increase of
IL-10 production and a decrease of TNF-α levels generated
by alveolar macrophages [59, 60].
6.PGE2 andL ungS tructur e
As mentioned above, the principal sources of PGE2 in
airways are the epithelial, endothelial, ﬁbroblast, and smooth
muscle cells. The epithelium is the ﬁrst barrier to pro-
tect against injury. Its cells create an anti-inﬂammatory
microenvironment that modulates the phenotype of local
antigen-presenting cells (APCs), regulating the activation
of local professional immune cells. A chronic state of
inﬂammation and wound healing exists in the lung as a part
of asthma pathology. Moreover, ﬁbroblasts actively migrate
and proliferate, synthesize and secrete extracellular matrix
components, and diﬀerentiate into myoﬁbroblasts. In this
process,PGE2 exertssigniﬁcantnegativeregulatoryfunctions
by inhibiting ﬁbroblast migration and chemotaxis with a
dominant role of EP2 receptors in the cAMP-dependent
inhibitory eﬀects [61, 62], thereby decreasing ﬁbroblast
proliferation through Epac-1 and subsequent Rap1 activa-
tion (cAMP eﬀectors) in a manner which is independent
of ERK1/2 participation [63]; furthermore, PGE2 inhibits
collagen expression by a PKA-mediated process which is
linked to EP2 and EP4 receptors [63].Impaired ex vivo COX-
2 function and PGE2 synthesis that characterize ﬁbroblast
during the evolution of airway ﬁbrosis may likewise promote
ﬁbrogenesis [64]. However, this inhibition of ﬁbrosis may
also occur through an inhibition of ﬁbroblast PAR1 expres-
sion, by PAR2-mediated generation of PGE2, one of the
protease-activated receptors coupled to G protein that pos-
sesses a unique mechanism of activation and induces COX
activation in a variety of cell types [65]. PAR-1 signalling is a
well-known proﬁbrotic pathway [66], so inhibition of PAR1
expression diminished pulmonary ﬁbrosis.
PGE2 has complex eﬀects on airway tone, and the
existence of several E-prostanoid receptors, each one with
diﬀerent signalling characteristics, has provided a possible4 Mediators of Inﬂammation
explanation for the seemingly contradictory actions of this
lipid mediator. Potent relaxant eﬀects on airway smooth
muscle have been observed; however, human studies with
aerosolized PGE2 have demonstrated inconsistent eﬀects on
airway tone, with most asthmatics showing a bronchodilator
response but some developing profound bronchoconstric-
tion requiring beta agonist rescue [36, 41, 43, 48].
7. Asthma and Nonasthmatic
EosinophilicBronchitis
Asthma is a complex chronic disease of the airways that has
been estimated to aﬀect over 300 million people worldwide,
andtheburdenislikelytoriseinthecomingdecades[64,67].
The inﬂammatory process in asthma is characterized by
inﬂammatory cells, mainly eosinophils, mast cells, basophils,
macrophages, and Th2 cells. These cells are involved in
the development of another hallmark of asthma as airway
hyperresponsiveness (AHR), reversible airway obstruction,
cough, mucus secretion, and structural changes by releasing
inﬂammatory mediators such as cytokines, chemokines,
growth factors, and chemical and lipid mediators [68, 69].
The complex pathogenesis of asthma is contributed to
by various cellular responses, based on the dysregulated
interaction between innate and adaptative immune systems.
Chronic cough is a common reason for referral to a
specialist, and asthma has consistently been reported among
the most common causes of chronic cough, accounting for
about 25% of such cases in adult nonsmokers [1, 70, 71].
The development of sputum induction has provided a safe
noninvasive method of assessing airway inﬂammation. One
of the most interesting early observations made using this
method was the identiﬁcation of a group of patients with
sputum eosinophilia identical to that seen asthma, but with
normal airway function. The physiological features of this
condition were diﬀerent from those of asthma, and Gibson
and colleagues suggested that the new disease should be
known as eosinophilic bronchitis [2]. The cough in patients
with nonasthmatic eosinophilic bronchitis (NAEB) responds
well to inhaled corticosteroids, though the same is not the
case for cough in patients without sputum eosinophilia.
NAEB is responsible for about 10% of cases of isolated
chronic cough referred for specialist investigation [72].
The etiology of asthma and NAEB is usually unknown,
although both can be associated with exposure to an
occupational sensitizer or to common inhaled allergens [73–
75]; thus, the triggers that cause eosinophilic bronchitis
without asthma are similar to the triggers of eosinophilic
bronchitis with asthma.
In patients with eosinophilic bronchitis, there is a
clear dissociation between sputum eosinophilia and airway
hyperresponsiveness. The pathophysiology of eosinophilic
bronchitis and the reason for the absence of airway hyper-
responsiveness in this disease remains unclear. One possible
explanation is that the eosinophilic airway inﬂammation
is less active than in asthma, with less release of eﬀector
mediators.Severalstudiesusingdiﬀerenttechniquestoassess
airway inﬂammation have shown that the inﬂammatory
component is very similar in patients with asthma and
NAEB [76]. Indeed, asthma and eosinophilic bronchitis
share many immunopathologic features including increased
number of eosinophils and mast cells in the superﬁcial
airway. In addition to airway eosinophilia, both conditions
are associated with reticular basement membrane thickening
and similar number of subepithelial T lymphocytes, mast
cells, and macrophages [76]. Eosinophilic bronchitis is
a disease characterized by increased expression of Th2
cytokines (IL-4, IL-5, IL-10, and IL-13) [77, 78]. These data
point to a dissociation between T-cell activation and the
abnormalities in airway physiology that characterize asthma
[79]. Such results suggest that Th2-mediated cytokines are
closely linked to eosinophilic inﬂammation, though they are
not necessarily associated with the physiologic hallmarks of
the asthmatic phenotype.
One aspect of the inﬂammatory response that might be
particularly important is the localization of mast cells in
the airway wall, since they are present within the airway
smooth muscle in asthma but not in NAEB [80]. Moreover,
insubjectswitheosinophilicbronchitis,CXCL8andCXCL10
concentrations were elevated in airway secretions. These
chemokines may play a key role in mast cell recruitment to
the superﬁcial airway in this condition [81]. Siddiqui and
colleagues have demonstrated that mast cells are microlo-
calized within the airway smooth muscle bundle in asthma,
which is associated with airway hyperresponsiveness [82].
Mast cells produce a variety of mediators that may interact
with bronchial smooth muscle and subsequently become
hyperresponsive to constrictive stimuli and proliferation
[83].
8.PGE2 inAsthma and NAEB
We recently found that induced sputum prostaglandin E2
(PGE2) concentrations are strikingly increased in subjects
with NAEB as compared with asthmatic and healthy subjects
[78]. This study illustrates that, like asthma, there is active
airway inﬂammation in eosinophilic bronchitis with release
of diﬀerent inﬂammatory mediators. These data suggest
that the diﬀerences in airway function observed in subjects
with NAEB and asthma may be due to diﬀerences in PGE2
production.
Brightling et al. [84] also found numerically higher levels
of PGE2 in sputum from patients with eosinophilic bronchi-
tis, though the diﬀerences were not statistically signiﬁcant as
compared with asthma patients. Recently, elevated sputum
PGE2 concentrations have been found in all patients with
chronic cough [73], although in this study cough variant
asthma and eosinophilic bronchitis patients were included in
the same group.
The diﬀerences in sputum PGE2 concentration between
asthmatic and eosinophilic bronchitis patients may be the
result of the implication of a diﬀerent degradation kinetic
or activity of enzymes in the synthesis and/or degradation
of products of arachidonic acid metabolism. It has been
recently shown that Th2 cytokines have speciﬁc eﬀects on
PGE synthase 1 and 15-PGDH enzymes in airway human
epithelial cells decreasing PGE2 [85].Mediators of Inﬂammation 5
We postulate that PGE2 elevation in patients with
eosinophilic bronchitis may have protective eﬀects against
the development of bronchial hyperresponsiveness. The
fact that PGE2 and its analogue have a number of bron-
choprotective and anti-inﬂammatory eﬀects in vitro [37]o r
after inhalation [36], as well as on allergen-induced airway
responses and airway inﬂammation in atopic asthma [38,
86], would support such a protective role. An imbalance
in the ratio of bronchoconstrictor (LTC4)a n db r o n c h o p r o -
tective (PGE2) lipid mediators may have a role in the
pathogenesis of eosinophilic bronchitis.
PGE2 can perform contrasting activities, which can thus
lead to bronchodilation and act as anti-inﬂammatory or
proinﬂammatory mediator substances in the lung [26].
Recently, several studies showed that the PGE2 protective
actions were mediated in large part by the EP2 receptors
[87, 88]. This protective action of PGE2 might not only
result in a direct eﬀect on airway smooth-muscle relaxation,
but also in the inhibition of many inﬂammatory processes
[89]. These data may explain why patients with eosinophilia
have normal tests of variable airway obstruction and airway
responsiveness and experience chronic cough due to high
PGE2 levels [90].
The pathogenesis of eosinophilic bronchitis might be the
opposite of that observed in aspirin-induced asthma. There
is increasing evidence that, by inhibiting cyclooxygenase-1,
the protective eﬀect exerted by endogenous prostaglandin
E2 on leukotriene generation by mast cells, eosinophils,
and macrophages in the airways is removed in aspirin-
induced asthma. In these patients with aspirin-induced
bronchoconstriction, a low production of PGE2 has been
observed, seemingly due to deﬁcient COX-2 regulation and
increased expression of leukotriene-C4 synthase [91].
9. Role of PGE2 inNAEB
Muscle hypertrophy and hyperplasia are characteristics of
asthmatic airways, and this increased layer of bronchial
smooth muscle contributes to AHR in asthmatic patients
[92, 93]. We hypothesized that high PGE2 levels in the lower
airways of NAEB patients constitute the essential regulatory
mediator causing inhibition of bronchial smooth muscle cell
proliferation (BSMC) and subsequent hyperresponsiveness
[94]. Thus, we demonstrated that when BSMCs are cultured
with induced sputum supernatant from NAEB patients, a
stronginhibitionofmusclecellproliferationtakesplace[94].
This inhibition was not due to the apoptotic eﬀect of sputum
supernatants or to diﬀerences in cytokine levels found in
sputum.Formalproofofthisﬁndingwastheaddition ofEP2
and EP4 antagonists to the culture recovery of the prolifera-
tion of smooth muscle cells. The lesser inhibition obtained
from sputum of asthmatic patients may be explained by the
absence or defectiveness of PGE2 p r o d u c t i o n ,a sw e l la sb y
diﬀerential EP2 and EP4 receptor expression from diﬀerent
pathologies. Similarly, Lundequist and colleagues recently
described a role for PGE2 in protecting the pulmonary












Figure 1: Hypothetical mechanisms through which PGE2 reduces
the AHR and in NAEB. (a) The PGE2 decreases the smooth muscle
proliferation producing a reduction of muscular hyperplasia, via
EP2 and EP4 receptors; (b) The PGE2 closes the KCa 3.1 channel,
preventing the migration of mastocytes by means of EP2. Both
mechanisms will decrease or inhibit airway hyperresponsiveness, a
relevant hallmark of asthma.
An alternative explanation of the diﬀerences in airway
function between asthma and NAEB is the diﬀerent local-
ization of mast cells within the airway wall. Siddiqui and
colleagues have demonstrated that mast cells are microlo-
calized within the airway smooth muscle bundle in asthma,
and this is associated with AHR [82]. Mast cells produce
a variety of mediators that may interact with BSM and
subsequently become hyperresponsive to constrictive stimuli
and proliferation [83]. We hypothesize that both mecha-
nisms may act synergistically (Figure 1). Recently, Duﬀya n d
colleagues reported that the engagement of the EP2 receptor
closes the K+ channel KCa 3.1 in human lung mast cells
and attenuates their migration [96]; thus, PGE2 present in
sputum supernatant from NAEB patients could close the KCa
3.1 channel and inhibit mast cell migration to the airway
wall and subsequently bring about microlocalization within
BSMC. Furthermore, in the inhibition of BSM proliferation
producedbyPGE2,theK+ channelKCa 3.1maybeimplicated
since activated K+ channels regulate human airway smooth
muscle proliferation [97].
Airway smooth muscle cells are the major eﬀector
cells regulating bronchomotor tone in response to several
mediators [98]. Some authors have reported that increased
vascularity, reticular basement membrane thickening, and
increased airway smooth muscle mass are features of
both diseases [99, 100]. However, the same authors have
recently reported that patients with asthma had airway
wall thickening, as opposed to subjects with NAEB, who6 Mediators of Inﬂammation
maintained airway patency without wall thickening [101]. In
addition,AHRandalteredairwaygeometrywerefoundtobe
correlated in asthma patients. Maintained proximal airway
patency in NAEB compared to the subjects with asthma may
protect against the development of AHR. In line with this,
Parketal.havereportedthatproximalairwaywallthickening
is not a feature of NAEB [102].
In conclusion, PGE2 present in induced sputum super-
natant from NAEB patients decreases BSMC proliferation,
probably due to simultaneous stimulation of EP2 and EP4
receptors with inhibitory activity. This protective eﬀect of
PGE2 may not only be the result of a direct action exerted
on airway smooth-muscle proliferation but also may be
attributable to the other anti-inﬂammatory actions. Thus,
PGE2 agonist receptors may become a novel therapeutic
approach for inﬂammatory respiratory diseases.
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